iOnctura

Uveal melanoma
#Cancer research #FDA #iOnctura #Ophthalmology #Orphan drugs #United States

FDA grants orphan drug status for uveal melanoma drug

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma.  Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More

#Cancer Research #News #Regulatory